D
Arch Biopartners Inc.
ACHFF
$1.20
-$0.061-4.84%
D
Sell
4/3/2025Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 4/3/2025 due to an increase in the valuation index, total return index and volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 4/3/2025 due to an increase in the valuation index, total return index and volatility index.
E
Sell
7/31/2024Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 7/31/2024 due to a large decline in the solvency index and valuation index. Debt to equity increased from -0.86 to -0.8.
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 7/31/2024 due to a large decline in the solvency index and valuation index. Debt to equity increased from -0.86 to -0.8.
D
Sell
1/4/2024Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
E
Sell
12/20/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 12/20/2023 due to a decline in the volatility index and valuation index.
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 12/20/2023 due to a decline in the volatility index and valuation index.
D
Sell
12/1/2023Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 12/1/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Operating cash flow increased 160.28% from -$701.1 to $422.6, earnings per share increased from -$0.0114 to -$0.0054, and EBIT increased 44.4% from -$610.6 to -$339.5.
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 12/1/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Operating cash flow increased 160.28% from -$701.1 to $422.6, earnings per share increased from -$0.0114 to -$0.0054, and EBIT increased 44.4% from -$610.6 to -$339.5.
E
Sell
7/21/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 7/21/2023 due to a decline in the volatility index and total return index.
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 7/21/2023 due to a decline in the volatility index and total return index.
D
Sell
7/6/2023Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
E
Sell
6/20/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 6/20/2023 due to a large decline in the solvency index, volatility index and total return index.
Arch Biopartners Inc. (ACHFF) was downgraded to E+ from D- on 6/20/2023 due to a large decline in the solvency index, volatility index and total return index.
D
Sell
3/14/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and growth index. EBIT declined 510.19% from -$258 to -$1.57M, earnings per share declined from -$0.0061 to -$0.0255, and operating cash flow declined 125.35% from $861.9 to -$218.5.
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and growth index. EBIT declined 510.19% from -$258 to -$1.57M, earnings per share declined from -$0.0061 to -$0.0255, and operating cash flow declined 125.35% from $861.9 to -$218.5.
D
Sell
2/23/2023Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D from D- on 02/23/2023.
Arch Biopartners Inc. (ACHFF) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 2/8/2023 due to a large decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0031 to -$0.0061, EBIT declined 95.75% from -$131.8 to -$258, and the quick ratio declined from 0.73 to 0.21.
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 2/8/2023 due to a large decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0031 to -$0.0061, EBIT declined 95.75% from -$131.8 to -$258, and the quick ratio declined from 0.73 to 0.21.
D
Sell
1/13/2023Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 1/13/2023 due to a decline in the total return index and volatility index.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 1/13/2023 due to a decline in the total return index and volatility index.
D
Sell
8/30/2022Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 8/30/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 11.22% from $362.8 to $322.1.
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 8/30/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 11.22% from $362.8 to $322.1.
C
Hold
3/4/2022Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the efficiency index and volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the efficiency index and volatility index.
D
Sell
1/31/2022Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 1/31/2022 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.65 to 0.83, and debt to equity declined from -1.18 to -1.33.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 1/31/2022 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.65 to 0.83, and debt to equity declined from -1.18 to -1.33.
D
Sell
11/23/2021Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
D
Sell
11/8/2021Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, valuation index and volatility index.
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, valuation index and volatility index.
D
Sell
2/4/2021Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 2/4/2021 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 269.57% from -$145.9 to -$539.2, total revenue declined 160.75% from $21.4 to -$13, and the quick ratio declined from 1.76 to 0.59.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 2/4/2021 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 269.57% from -$145.9 to -$539.2, total revenue declined 160.75% from $21.4 to -$13, and the quick ratio declined from 1.76 to 0.59.
D
Sell
11/27/2020Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 11/27/2020 due to a major increase in the total return index and valuation index.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 11/27/2020 due to a major increase in the total return index and valuation index.
D
Sell
11/9/2020Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 11/9/2020 due to a decline in the total return index and valuation index.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 11/9/2020 due to a decline in the total return index and valuation index.
D
Sell
10/22/2020Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 10/22/2020 due to an increase in the total return index and volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 10/22/2020 due to an increase in the total return index and volatility index.
D
Sell
10/2/2020Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 10/2/2020 due to a large decline in the growth index and solvency index. EBIT declined 28,272.22% from -$5.4 to -$1.53M, earnings per share declined from -$0.0012 to -$0.0264, and total revenue declined 2.73% from $22 to $21.4.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 10/2/2020 due to a large decline in the growth index and solvency index. EBIT declined 28,272.22% from -$5.4 to -$1.53M, earnings per share declined from -$0.0012 to -$0.0264, and total revenue declined 2.73% from $22 to $21.4.
D
Sell
5/18/2020Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 5/18/2020 due to an increase in the volatility index and total return index.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 5/18/2020 due to an increase in the volatility index and total return index.
D
Sell
5/1/2020Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
Arch Biopartners Inc. (ACHFF) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
C
Hold
3/4/2020Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D on 3/4/2020 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 26.86% from -$713.3 to -$521.7, earnings per share increased from -$0.0125 to -$0.0094, and net income increased 24.7% from -$737.6 to -$555.4.
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D on 3/4/2020 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 26.86% from -$713.3 to -$521.7, earnings per share increased from -$0.0125 to -$0.0094, and net income increased 24.7% from -$737.6 to -$555.4.
D
Sell
8/30/2019Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 8/30/2019 due to a significant decline in the efficiency index, total return index and solvency index.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 8/30/2019 due to a significant decline in the efficiency index, total return index and solvency index.
D
Sell
3/4/2019Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 3/4/2019 due to a significant increase in the efficiency index and valuation index.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D on 3/4/2019 due to a significant increase in the efficiency index and valuation index.
D
Sell
12/18/2018Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 12/18/2018 due to a major decline in the total return index and volatility index.
Arch Biopartners Inc. (ACHFF) was downgraded to D from D+ on 12/18/2018 due to a major decline in the total return index and volatility index.
D
Sell
10/29/2018Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 10/29/2018 due to a substantial decline in the total return index.
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 10/29/2018 due to a substantial decline in the total return index.
C
Hold
10/4/2018Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 10/4/2018 due to a significant increase in the total return index, solvency index and volatility index.
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 10/4/2018 due to a significant increase in the total return index, solvency index and volatility index.
D
Sell
3/2/2018Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 3/2/2018 due to a significant decline in the efficiency index, growth index and volatility index. Operating cash flow declined 72.88% from -$164.8 to -$284.9, earnings per share declined from -$0.0032 to -$0.0049, and net income declined 53.01% from -$175.8 to -$269.
Arch Biopartners Inc. (ACHFF) was downgraded to D+ from C- on 3/2/2018 due to a significant decline in the efficiency index, growth index and volatility index. Operating cash flow declined 72.88% from -$164.8 to -$284.9, earnings per share declined from -$0.0032 to -$0.0049, and net income declined 53.01% from -$175.8 to -$269.
C
Hold
1/30/2018Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 1/30/2018 due to a large increase in the total return index, volatility index and growth index. EBIT increased 82.67% from -$965.3 to -$167.3, earnings per share increased from -$0.0177 to -$0.0032, and operating cash flow increased 9.35% from -$181.8 to -$164.8.
Arch Biopartners Inc. (ACHFF) was upgraded to C- from D+ on 1/30/2018 due to a large increase in the total return index, volatility index and growth index. EBIT increased 82.67% from -$965.3 to -$167.3, earnings per share increased from -$0.0177 to -$0.0032, and operating cash flow increased 9.35% from -$181.8 to -$164.8.
D
Sell
8/31/2017Upgraded
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D- on 8/31/2017 due to a significant increase in the efficiency index, volatility index and valuation index.
Arch Biopartners Inc. (ACHFF) was upgraded to D+ from D- on 8/31/2017 due to a significant increase in the efficiency index, volatility index and valuation index.
D
Sell
6/1/2017Downgrade
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D+ on 6/1/2017 due to a significant decline in the efficiency index and valuation index.
Arch Biopartners Inc. (ACHFF) was downgraded to D- from D+ on 6/1/2017 due to a significant decline in the efficiency index and valuation index.
D
Sell
3/13/2017Upgraded
Arch Biopartners Inc. (FOIFF) was upgraded to D+ from D- on 3/13/2017 due to a significant increase in the efficiency index, solvency index and total return index. Net income increased 33.26% from -$264.3 to -$176.4.
Arch Biopartners Inc. (FOIFF) was upgraded to D+ from D- on 3/13/2017 due to a significant increase in the efficiency index, solvency index and total return index. Net income increased 33.26% from -$264.3 to -$176.4.
D
Sell
3/11/2016Downgrade
Arch Biopartners, Inc. (FOIFF) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, solvency index and total return index. Debt to equity increased from 2.38 to 89.14, and the quick ratio declined from 3.61 to 3.47.
Arch Biopartners, Inc. (FOIFF) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, solvency index and total return index. Debt to equity increased from 2.38 to 89.14, and the quick ratio declined from 3.61 to 3.47.
D
Sell
3/12/2015Downgrade
Arch Biopartners, Inc. (FOIFF) was downgraded to D from C- on 3/12/2015 due to a significant decline in the efficiency index.
Arch Biopartners, Inc. (FOIFF) was downgraded to D from C- on 3/12/2015 due to a significant decline in the efficiency index.
C
Hold
3/4/2015Upgraded
Arch Biopartners, Inc. (FOIFF) was upgraded to C- from D on 3/4/2015 due to a significant increase in the efficiency index, solvency index and valuation index. Net income increased 120.36% from -$143.4 to -$316, and debt to equity declined from -54.59 to 0.
Arch Biopartners, Inc. (FOIFF) was upgraded to C- from D on 3/4/2015 due to a significant increase in the efficiency index, solvency index and valuation index. Net income increased 120.36% from -$143.4 to -$316, and debt to equity declined from -54.59 to 0.
D
Sell
9/25/2014None
OTC PK
04/04/2025 12:22PM Eastern
Quotes delayed
